Valion Bio, Inc.

VBIO Healthcare Biotechnology

Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023.

Revenue
+15.9%
EPS
+0.91%
Free cash flow
−189.0%

Quarter to June 2026, against a year earlier

0.51 0.01 +2.00%
Market cap
$1.1M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
3/9
Altman Z
−21.96
Beneish M
48.80
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
3.38 8.65 13.01 3.74
Total non-current assets
29.09 29.56 18.60 2.49
Total Assets
32.47 38.22 31.61 6.23
Total current liabilities
3.05 2.62 0.65 0.64
Total non-current liabilities
17.54 17.05 6.79 —
Total liabilities
20.59 19.67 7.44 0.64
Common Equity (Total)
4.25 11.06 16.80 5.59
Shareholders Equity (Total)
11.89 18.55 24.17 5.59
Total Debt
7.39 6.90 6.45 —

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 26 Oct 2026